Rhumbline Advisers Sells 5,680 Shares of Neurocrine Biosciences, Inc. $NBIX

Rhumbline Advisers lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.8% during the third quarter, HoldingsChannel.com reports. The fund owned 303,510 shares of the company’s stock after selling 5,680 shares during the period. Rhumbline Advisers’ holdings in Neurocrine Biosciences were worth $42,607,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Golden State Wealth Management LLC increased its holdings in shares of Neurocrine Biosciences by 120.5% in the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after purchasing an additional 100 shares during the period. Eastern Bank bought a new position in Neurocrine Biosciences in the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. raised its holdings in shares of Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. Quent Capital LLC bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at about $32,000. Finally, MAI Capital Management grew its holdings in shares of Neurocrine Biosciences by 101.2% during the second quarter. MAI Capital Management now owns 328 shares of the company’s stock worth $41,000 after purchasing an additional 165 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Stock Up 0.8%

Neurocrine Biosciences stock opened at $124.12 on Friday. The firm has a fifty day simple moving average of $140.14 and a two-hundred day simple moving average of $140.44. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $160.18. The company has a market capitalization of $12.46 billion, a PE ratio of 26.64, a P/E/G ratio of 0.58 and a beta of 0.31.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing the consensus estimate of $2.36 by ($0.48). The company had revenue of $805.50 million during the quarter, compared to analysts’ expectations of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The firm’s quarterly revenue was up 28.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.69 EPS. As a group, equities analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on NBIX. Mizuho lifted their target price on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. UBS Group dropped their price objective on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Zacks Research lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. TD Cowen raised their price target on Neurocrine Biosciences from $175.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Finally, Truist Financial cut their price objective on Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Sixteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average target price of $177.42.

Insider Buying and Selling

In other news, Director Leslie V. Norwalk sold 1,190 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total value of $184,557.10. Following the transaction, the director owned 6,239 shares in the company, valued at approximately $967,606.51. This trade represents a 16.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the sale, the chief executive officer owned 140,407 shares of the company’s stock, valued at $18,632,008.90. This represents a 20.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 61,966 shares of company stock worth $8,625,166. Company insiders own 4.80% of the company’s stock.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Multiple analysts reiterated Buy/Outperform ratings and raised some price targets (Citigroup to $204, Bank of America reiterated Buy with a $190 target, Needham nudged to $185), signaling continued confidence in Ingrezza durability and pipeline upside. Analyst moves (Benzinga / TipRanks)
• Positive Sentiment: Q4 revenue grew strongly (~28% YoY to ~$805.5M) and company commentary highlighted Ingrezza sales growth and emerging uptake of pipeline assets — supports longer-term revenue trajectory. Earnings highlights (Yahoo)
• Neutral Sentiment: Deeper analysis pieces discuss growth beyond Ingrezza and portfolio opportunities that could drive medium-term upside but caution that 2026 may be less eventful. Useful for investors assessing longer-horizon thesis. Seeking Alpha: Growth Beyond Ingrezza
• Neutral Sentiment: Full Q4 earnings call transcripts and analyst note compilations are available for investors wanting primary commentary on guidance, expense cadence, and pipeline timelines. Review for detail before trading on headlines. Earnings transcripts & summaries
• Negative Sentiment: EPS missed expectations (Q4 EPS ~$1.88 vs. several consensus figures higher), and management issued cautious 2026 guidance — the combination sparked downside pressure and short-term uncertainty. Zacks: Q4 EPS lag
• Negative Sentiment: Some firms trimmed price targets or downgraded to Market Perform (BMO to $140; RBC and Wells Fargo trimmed targets though keeping Outperform/Overweight designations), reflecting more cautious near-term outlooks. Price target changes (Benzinga)
• Negative Sentiment: Market commentary highlights the stock’s sharp pullback after guidance and the EPS miss — articles explaining recent 8%+ decline underscore the sentiment risk if sales or cost pressures persist. AAII: Why NBIX is down

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.